PPARG and lung carcinoma: Although recently a clinical retrospective database analysis had reported that PPARγ agonists (thiazolidinediones) reduced lung cancer risk in diabetic patients [10], there was no rational explanation and the mechanistic data explaining PPARγ action in lung cancer are controversial.